Why ZEJULA® (niraparib) for Recurrent Ovarian Cancer?

Why ZEJULA?

ZEJULA is a once-daily oral maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, after the cancer has completely or partially responded to the most recent chemotherapy.1

Thumbnail of a clip-board with a graph

Benefits of ZEJULA


See clinical trial data and learn how ZEJULA worked for women with recurrent ovarian cancer.

see the data

Thumbnail representing a woman

Is ZEJULA Right for You?


Find out if ZEJULA can help you with your recurrent ovarian, fallopian tube, or primary peritoneal cancer.

find out more

Thumbnail representing ZEJULA

Taking ZEJULA


Get details on ZEJULA dosing and handling, as well as information about how your doctor will monitor your treatment.

Information for you

Reference: 1. ZEJULA [package insert]. Waltham, MA: TESARO, Inc.; June 2019.

Back to Top